Hematology

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

April 11th 2025

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

April 10th 2025

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
Immune Microenvironment a Key Target in CLL

April 8th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com
Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

April 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality
March 22nd 2019

FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality

Samantha DiGrande
This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.
Site Logo
March 21st 2019

NCCN Panel Digs Into Reality of CAR T-Cell Reimbursement

Mary Caffrey
A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.
Will CMS' CAR T-Cell Therapy Payment Plan Leave Out Community Practices?
March 14th 2019

Will CMS' CAR T-Cell Therapy Payment Plan Leave Out Community Practices?

Mary Caffrey
There is concern among stakeholder groups that references to “hospital” could mean that community practices would be unable to be reimbursed by Medicare under a proposed National Coverage Determination.
Once-Weekly Carfilzomib as Safe, Effective as Twice-Weekly Treatment in Newly Diagnosed MM
March 13th 2019

Once-Weekly Carfilzomib as Safe, Effective as Twice-Weekly Treatment in Newly Diagnosed MM

Jaime Rosenberg
Pooled data from 2 studies revealed that once-weekly administration of 70 mg/m2 of carfilzomib is as safe and effective in newly diagnosed multiple myeloma (MM) as twice-weekly administration of 36 mg/m2 of the treatment while also providing a more convenient treatment schedule.
Addressing Disparities in End-of-Life Care in Blood Cancers
March 8th 2019

Addressing Disparities in End-of-Life Care in Blood Cancers

Laura Joszt, MA
While use of palliative care at the end of life has increased, disparities remain, and not all patients who are terminally ill with blood cancers are having discussions about their goals of care at the end of life.
Carfilzomib Regimen Results in Longer Time to Next Treatment, Improved Survival in RRMM
March 6th 2019

Carfilzomib Regimen Results in Longer Time to Next Treatment, Improved Survival in RRMM

Jaime Rosenberg
Compared with other drug regimens, a carfilzomib-based regimen resulted in longer time to next treatment, as well as longer overall survival and improved 24-month survival, among patients with relapsed or refractory multiple myeloma (RRMM).
Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds
March 2nd 2019

Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds

Laura Joszt, MA
Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.
Palliative Care, Hospice Improves End-of-Life Care Among Patients With Hematologic Malignancies
February 23rd 2019

Palliative Care, Hospice Improves End-of-Life Care Among Patients With Hematologic Malignancies

Jaime Rosenberg
Patients with hematologic malignancies often receive intensive care at the end of life (EOL), but new research has demonstrated that hospice services and palliative care are associated with significantly improved EOL care quality.
Once-Weekly Carfilzomib Safe, Effective in All Age Groups of Patients With RRMM
February 20th 2019

Once-Weekly Carfilzomib Safe, Effective in All Age Groups of Patients With RRMM

Laura Joszt, MA
Patients of all ages see benefits with once-weekly carfilzomib compared with a twice-weekly dose, according to an analysis of the phase 3 A.R.R.O.W. trial.
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15th 2019

CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy

Mary Caffrey Allison Inserro
The payment model will gather data that will be used to create a long-term model for patients not enrolled in studies or registries.
Preparing Patients and the Health System for Curative Therapies in the Pipeline
February 12th 2019

Preparing Patients and the Health System for Curative Therapies in the Pipeline

Laura Joszt, MA
Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.
Identifying Patient Preferences in MM Treatment Improves Shared Decision Making
February 10th 2019

Identifying Patient Preferences in MM Treatment Improves Shared Decision Making

Laura Joszt, MA
Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.
Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML
February 7th 2019

Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML

David Bai, PharmD
Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.
Obesity-Related Cancers Are on the Rise in Young Adults
February 7th 2019

Obesity-Related Cancers Are on the Rise in Young Adults

Kelly Davio
A recent observational study, which used data covering more than half of the US population, found that the incidence of cancer linked to obesity is on the rise in young adults.
Long Noncoding RNAs Contribute to Prominent Signaling Pathways in BCP-ALL
February 2nd 2019

Long Noncoding RNAs Contribute to Prominent Signaling Pathways in BCP-ALL

David Bai, PharmD
Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.
FDA Approves Ibrutinib Combination as Frontline Treatment for CLL
January 29th 2019

FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

Jaime Rosenberg
The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).
Two Studies Look at Factors Impacting Response to Multiple Myeloma Treatment
January 26th 2019

Two Studies Look at Factors Impacting Response to Multiple Myeloma Treatment

David Bai, PharmD
Two recent studies analyzed patients with multiple myeloma to identify factors that impacted response to therapy.
Treatment Advances Make Supportive Care More Important in Multiple Myeloma
January 22nd 2019

Treatment Advances Make Supportive Care More Important in Multiple Myeloma

Laura Joszt, MA
As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.
Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose
January 19th 2019

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose

Laura Joszt, MA
Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.
Site Logo
January 19th 2019

Policy

Updates from the annual ASH meeting, December 2018.
Tisagenlecleucel Shows Promise for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
January 17th 2019

Tisagenlecleucel Shows Promise for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David Bai, PharmD
Published results confirm the efficacy of tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.
Maintenance Therapy for Multiple Myeloma Needs Improvement Beyond Lenalidomide, Study Says
January 12th 2019

Maintenance Therapy for Multiple Myeloma Needs Improvement Beyond Lenalidomide, Study Says

David Bai, PharmD
Maintenance therapy with lenalidomide remains a standard of care for patients with multiple myeloma. However, optimizing maintenance therapy in this setting is required as a result of lenalidomide’s lack of overall survival benefit and improvement in outcomes for patients with high-risk cytogenic abnormalities, according to a recent study.
BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference
January 8th 2019

BMS, Celgene Discuss $74 Billion Acquisition During JP Morgan Healthcare Conference

Jaime Rosenberg
Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages
January 5th 2019

Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages

As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.
Radiotherapy Plus Chemotherapy Improves Survival in Pediatric Patients With Hodgkin Lymphoma
January 5th 2019

Radiotherapy Plus Chemotherapy Improves Survival in Pediatric Patients With Hodgkin Lymphoma

Laura Joszt, MA
Pediatric patients with early-stage Hodgkin lymphoma who are treated with chemotherapy followed by radiotherapy, known as combined modality therapy, have an improved 5-year survival rate compared with patients treated with chemotherapy alone.
Dr Elizabeth Griffiths Outlines Recent Approvals in AML
January 4th 2019

Dr Elizabeth Griffiths Outlines Recent Approvals in AML

Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center discusses recent approvals for acute myeloid leukemia (AML).
Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Later Tumors
December 29th 2018

Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Later Tumors

David Bai, PharmD
Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.
Dr Alison Moskowitz Discusses Survival Disparities in Hodgkin Lymphoma
December 29th 2018

Dr Alison Moskowitz Discusses Survival Disparities in Hodgkin Lymphoma

Patients who are over 60 with Hodgkin lymphoma have much lower survival rates than patients who are under 60, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.
Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS
December 28th 2018

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS

Laura Joszt, MA
Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.
Dr Brian Koffman Highlights Incredible Responses to CLL Treatments
December 20th 2018

Dr Brian Koffman Highlights Incredible Responses to CLL Treatments

There have been incredible responses to treatments for chronic lymphocytic leukemia (CLL), but there remains a tremendous unmet need for patients, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
<1
...
111213141516171819
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo